Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study

Objectives To examine: (1) changes in polypharmacy in 1997, 2002, 2007 and 2012 and; (2) changes in potentially inappropriate prescribing (PIP) prevalence and the relationship between PIP and polypharmacy in individuals aged ≥65 years over this period in Ireland. Methods This repeated cross-sectional study using pharmacy claims data included all individuals eligible for the General Medical Services scheme in the former Eastern Health Board region of Ireland in 1997, 2002, 2007 and 2012 (range 338 025–539 752 individuals). Outcomes evaluated were prevalence of polypharmacy (being prescribed ≥5 regular medicines) and excessive polypharmacy (≥10 regular medicines) in all individuals and PIP prevalence in those aged ≥65 years determined by 30 criteria from the Screening Tool for Older Persons’ Prescriptions. Results The prevalence of polypharmacy increased from 1997 to 2012, particularly among older individuals (from 17.8% to 60.4% in those aged ≥65 years). The adjusted incident rate ratio for polypharmacy in 2012 compared to 1997 was 4.16 (95% CI 3.23 to 5.36), and for excessive polypharmacy it was 10.53 (8.58 to 12.91). Prevalence of PIP rose from 32.6% in 1997 to 37.3% in 2012. High-dose aspirin and digoxin prescribing decreased over time, but long-term proton pump inhibitors at maximal dose increased substantially (from 0.8% to 23.8%). The odds of having any PIP in 2012 were lower compared to 1997 after controlling for gender and level of polypharmacy, OR 0.39 (95% CI 0.39 to 0.4). Conclusions Accounting for the marked increase in polypharmacy, prescribing quality appears to have improved with a reduction in the odds of having PIP from 1997 to 2012. With growing numbers of people taking multiple regular medicines, strategies to address the related challenges of polypharmacy and PIP are needed.

[1]  F. Sanfilippo,et al.  Are older Western Australians exposed to potentially inappropriate medications according to the Beers Criteria? A 13‐year prevalence study , 2014, Australasian journal on ageing.

[2]  C. Teljeur,et al.  Potentially Inappropriate Prescribing and Vulnerability and Hospitalization in Older Community-Dwelling Patients , 2014, The Annals of pharmacotherapy.

[3]  P. Gallagher,et al.  STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. , 2008, International journal of clinical pharmacology and therapeutics.

[4]  Cordula Wagner,et al.  Potentially inappropriate medication use among elderly home care patients in Europe. , 2005, JAMA.

[5]  Reamer L. Bushardt,et al.  Polypharmacy: Misleading, but manageable , 2008, Clinical interventions in aging.

[6]  J. Tobert,et al.  Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors , 2003, Nature Reviews Drug Discovery.

[7]  N. Kerse,et al.  Interventions to improve the appropriate use of polypharmacy for older people. , 2018, The Cochrane database of systematic reviews.

[8]  M. Olfson,et al.  Benzodiazepine use in the United States. , 2015, JAMA psychiatry.

[9]  Sirpa Hartikainen,et al.  Use of medications and polypharmacy are increasing among the elderly. , 2002, Journal of clinical epidemiology.

[10]  B. Guthrie,et al.  Adapting clinical guidelines to take account of multimorbidity , 2012, BMJ : British Medical Journal.

[11]  D. Cook,et al.  What Factors Predict Potentially Inappropriate Primary Care Prescribing in Older People? , 2008, Drugs & aging.

[12]  D. Morgan,et al.  Update on medical overuse. , 2015, JAMA internal medicine.

[13]  M. Kreiner,et al.  The Changing Face of Chronic Illness Management in Primary Care: A Qualitative Study of Underlying Influences and Unintended Outcomes , 2012, The Annals of Family Medicine.

[14]  S. Ebrahim The medicalisation of old age , 2002, BMJ : British Medical Journal.

[15]  R. Payne,et al.  Polypharmacy and medicines optimisation: Making it safe and sound , 2013 .

[16]  T. Fahey,et al.  Longitudinal prevalence of potentially inappropriate medicines and potential prescribing omissions in a cohort of community-dwelling older people , 2015, European Journal of Clinical Pharmacology.

[17]  Göran Petersson,et al.  Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008 , 2010, BMC clinical pharmacology.

[18]  M J Ball,et al.  Healthcare Informatics , 2009, Encyclopedia of Database Systems.

[19]  C. Teljeur,et al.  Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. , 2014, British journal of clinical pharmacology.

[20]  Lisa M. Schwartz,et al.  Winding back the harms of too much medicine , 2013, BMJ : British Medical Journal.

[21]  C. Teljeur,et al.  Proton pump inhibitors: potential cost reductions by applying prescribing guidelines , 2012, BMC Health Services Research.

[22]  R. Ocaña-Riola,et al.  Optimizing elderly pharmacotherapy: polypharmacy vs. undertreatment. Are these two concepts related? , 2014, European Journal of Clinical Pharmacology.

[23]  Bruce Guthrie,et al.  High risk prescribing in primary care patients particularly vulnerable to adverse drug events: cross sectional population database analysis in Scottish general practice , 2011, BMJ : British Medical Journal.

[24]  S. Wyke,et al.  Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study , 2012, The Lancet.

[25]  Mph Cynthia M. Boyd MD,et al.  Evidence-Based Medicine and the Hard Problem of Multimorbidity , 2013, Journal of General Internal Medicine.

[26]  L. Smeeth,et al.  Mass treatment with statins , 2014, BMJ : British Medical Journal.

[27]  C. Hughes,et al.  Going beyond the numbers - a call to redefine polypharmacy. , 2014, British journal of clinical pharmacology.

[28]  Timothy R. Huerta,et al.  National use of proton pump inhibitors from 2007 to 2011. , 2014, JAMA internal medicine.

[29]  M. Goulding,et al.  Inappropriate medication prescribing for elderly ambulatory care patients. , 2004, Archives of internal medicine.

[30]  Deborah Grady,et al.  Less is more: how less health care can result in better health. , 2010, Archives of internal medicine.

[31]  E. Mulvey,et al.  Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. , 1995, Psychological bulletin.

[32]  S. Haider,et al.  Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992 - 2002. , 2007, International journal of clinical pharmacology and therapeutics.

[33]  B. Vanderhoff,et al.  Proton pump inhibitors: an update. , 2002, American family physician.

[34]  D. L. Couteur,et al.  Discontinuing drug treatments , 2014, BMJ : British Medical Journal.

[35]  G. Petersson,et al.  Trends in Inappropriate Drug Therapy Prescription in the Elderly in Sweden from 2006 to 2013: Assessment Using National Indicators , 2014, Drugs & Aging.

[36]  J. Gurwitz Polypharmacy: a new paradigm for quality drug therapy in the elderly? , 2004, Archives of internal medicine.

[37]  R. Aparasu,et al.  Polypharmacy trends in office visits by the elderly in the United States, 1990 and 2000. , 2005, Research in social & administrative pharmacy : RSAP.

[38]  R. Payne,et al.  Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. , 2014, British journal of clinical pharmacology.